Stock Events

Stock Events

Traws Pharma 

$0.6060
123
+$0.02+3.52% 11:54 Today

Statistics

Day High
0.5908
Day Low
0.5902
52W High
3.27
52W Low
0.43
Volume
2,100
Avg. Volume
-
Mkt Cap
9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-9.16
-5.41
-1.66
2.09
Expected EPS
-0.205
Actual EPS
N/A

Financials

328.67%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.79MRevenue
9.17MNet Income

Analyst Ratings

1.00Average Price Target
The highest estimate is 1.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRAW. It's not an investment recommendation.
Apple
19
AAPL
Tesla
19
TSLA
Amazon
16
AMZN
Microsoft
14
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences is a biopharmaceutical company that develops drugs for cancer, a direct competition to Onconova's focus on cancer therapeutics.
AMGEN
AMGN
Mkt Cap237.52B
Amgen focuses on human therapeutics, including treatments for cancer, making it a competitor in the oncology space.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, directly competing with Onconova's cancer therapy research.
Pfizer
PFE
Mkt Cap159.99B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including oncology, competing in the cancer treatment market.
Merck
MRK
Mkt Cap376.37B
Merck is known for its cancer drugs and vaccines, making it a competitor in the oncology sector.
Novartis
NVS
Mkt Cap301.95B
Novartis focuses on patented medicines for a range of diseases, including cancer, competing with Onconova's therapeutic developments.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie operates in the pharmaceuticals sector, focusing on oncology, among other areas, making it a competitor.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca operates in the biopharmaceutical sector, focusing on the development of cancer drugs, directly competing with Onconova.
Lilly(Eli) &
LLY
Mkt Cap1.12T
Eli Lilly and Company develops a wide range of pharmaceutical products, including cancer treatments, making it a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals focuses on developing medicines for serious medical conditions, including cancer, competing in the same space as Onconova.

Holdings

About

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Show more...
CEO
Iain D. Dukes
Employees
7
Country
United States
ISIN
US68232V8845
WKN
000A40PJ7

Listings

F
DE
0T20.F
MU
DE
0T20.MU
STU
DE
0T20.STU
BATS
US
ONTX

0 Comments

Share your thoughts

FAQ

What is Traws Pharma stock price today?▼
The current price of TRAW is $0.61 USD — it has increased by +3.52% in the past 24 hours. Watch Traws Pharma stock price performance more closely on the chart.
What is Traws Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Traws Pharma stocks are traded under the ticker TRAW.
Is Traws Pharma stock price growing?▼
TRAW stock has risen by +10.45% compared to the previous week, the month change is a +14.11% rise, over the last year Traws Pharma has showed a -58.77% decrease.
What is Traws Pharma market cap?▼
Today Traws Pharma has the market capitalization of 9M
When is the next Traws Pharma earnings date?▼
Traws Pharma is going to release the next earnings report on November 12, 2026.
What were Traws Pharma earnings last quarter?▼
TRAW earnings for the last quarter are -0.16 USD per share, whereas the estimation was -0.34 USD resulting in a +52.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Traws Pharma revenue for the last year?▼
Traws Pharma revenue for the last year amounts to 2.79M USD.
What is Traws Pharma net income for the last year?▼
TRAW net income for the last year is 9.17M USD.
How many employees does Traws Pharma have?▼
As of August 28, 2026, the company has 7 employees.
In which sector is Traws Pharma located?▼
Traws Pharma operates in the Health & Wellness sector.
When did Traws Pharma complete a stock split?▼
The last stock split for Traws Pharma was on September 23, 2024 with a ratio of 1:25.
Where is Traws Pharma headquartered?▼
Traws Pharma is headquartered in NEWTOWN, United States.